Sulfamoylbenzamide derivatives as antiviral agents against HBV infection

US9758477B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9758477-B2
Application numberUS-201514975239-A
CountryUS
Kind codeB2
Filing dateDec 18, 2015
Priority dateJul 1, 2011
Publication dateSep 12, 2017
Grant dateSep 12, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides sulfamoylbenzamide derivatives, and pharmaceutical compositions thereof. In certain embodiments, the compounds and pharmaceutical compositions of the invention inhibit pregenomic RNA encapsidation. In other embodiments, the compounds and pharmaceutical compositions of the invention are useful for treating Hepatitis B virus (HBV) infection.

First claim

Opening claim text (preview).

What is claimed is: 1. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier, at least one compound of formula (III): wherein: R 10 is selected from the group consisting of H, CH 3 , Cl and Br; R y is selected from the group consisting of or a pharmaceutically acceptable salt thereof, and at least one additional agent that treats Hepatitis B virus (HBV) infection. 2. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier, at least one compound selected from the group consisting of: 3-(Azepane-1-sulfonyl)-N-benzyl-4-chloro-benzamide, N-Benzyl-4-chloro-3-(piperidine-1-sulfonyl)-benzamide, N-Benzyl-4-methyl-3-(4-methyl-piperidine-1-sulfonyl)-benzamide, N-Benzyl-3-benzylsulfamoyl-4-methyl-benzamide, 3-(3-Benzylcarbamoyl-benzenesulfonylamino)-benzoic acid, N-Benzyl-4-bromo-3-diethylsulfamoyl-benzamide, any pharmaceutically acceptable salt thereof, and any mixtures thereof; and at least one additional agent that treats Hepatitis B virus (HBV) infection.

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • for RNA viruses · CPC title

  • for DNA viruses · CPC title

  • 1,4-Oxazines, e.g. morpholine · CPC title

  • Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9758477B2 cover?
The present invention provides sulfamoylbenzamide derivatives, and pharmaceutical compositions thereof. In certain embodiments, the compounds and pharmaceutical compositions of the invention inhibit pregenomic RNA encapsidation. In other embodiments, the compounds and pharmaceutical compositions of the invention are useful for treating Hepatitis B virus (HBV) infection.
Who is the assignee on this patent?
Univ Drexel, Baruch S Blumberg Inst
What technology area does this patent fall under?
Primary CPC classification C07C311/46. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).